XML 80 R60.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Assets and Liabilities Measured at Fair Value - Narrative (Details) | 3 Months Ended |  |
--- | --- | --- | ---
Mar. 31, 2019 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Financial assets and liabilities subject to fair value measurements |  |  |
Contingent consideration payable |  | $ 20,339,000 | $ 25,825,000
Milestone payment, stock issued as consideration | $ 771,804 |  |
Level 3 |  |  |
Financial assets and liabilities subject to fair value measurements |  |  |
Contingent consideration payable |  | 20,339,000 | $ 25,825,000
Callidus | Clinical and Regulatory Approval Milestones | ATB-200 Pompe Program | Probability weighted discounted cash flow |  |  |
Financial assets and liabilities subject to fair value measurements |  |  |
Contingent consideration payable |  | $ 18,883,000 |
Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Minimum |  |  |
Financial assets and liabilities subject to fair value measurements |  |  |
Contingent consideration, measurement input |  | 0.75 |
Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Maximum |  |  |
Financial assets and liabilities subject to fair value measurements |  |  |
Contingent consideration, measurement input |  | 0.88 |
Callidus | Clinical and Regulatory Approval Milestones | Level 3 | Discount rate | ATB-200 Pompe Program |  |  |
Financial assets and liabilities subject to fair value measurements |  |  |
Contingent consideration, measurement input |  | 0.075 |

X
- Definition Contingent Consideration, Measurement Input + References No definition available. + Details
Name: | fold_ContingentConsiderationMeasurementInput
Namespace Prefix: | fold_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone Payment, Stock Issued As Consideration + References No definition available. + Details
Name: | fold_MilestonePaymentStockIssuedAsConsideration
Namespace Prefix: | fold_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |